Paula
Rodríguez Otero
Consultora Médica
Centro de Investigación Biomédica en Red de Cáncer
Madrid, EspañaCentro de Investigación Biomédica en Red de Cáncer-ko ikertzaileekin lankidetzan egindako argitalpenak (5)
2024
-
Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma
Haematologica
-
Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance
Journal of Clinical Oncology, Vol. 42, Núm. 27, pp. 3247-3256
2023
-
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network
The Lancet Oncology, Vol. 24, Núm. 6, pp. e255-e269
2022
-
CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome
Science Advances, Vol. 8, Núm. 39
-
Landscape and clinical significance of long noncoding RNAs involved in multiple myeloma expressed fusion transcripts
American Journal of Hematology